Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PolyMedix Inc.

This article was originally published in Start Up

Executive Summary

PolyMedix uses a suite of proprietary, patented computational tools to create simple, easily synthesized organic small molecule compounds that mimic the activity of host defense proteins. The company's first focus is to create antibiotic candidates, and eventually, drugs for cancer and cardiovascular disease. It will seek nearer-term revenues from materials applications of its technologies.

You may also be interested in...

Signaling beneath the Cell Surface

Designing molecules that target protein-protein interactions in transmembrane proteins, where antibodies and fragments cannot penetrate, has been difficult. Using computational methods, a group at Penn has created novel peptides that could offer a new class of reagents for studying membrane-protein folding, assembly, and signal transduction. More broadly, they could provide access to an entire new class of targets for the design of therapeutics and drug delivery systems

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts